M&A Deal Summary

Genmab Acquires ProfoundBio

On April 3, 2024, Genmab acquired life science company ProfoundBio for 1.8B USD

Acquisition Highlights
  • This is Genmab’s 1st transaction in the Life Science sector.
  • This is Genmab’s largest (disclosed) transaction.
  • This is Genmab’s 1st transaction in the United States.
  • This is Genmab’s 1st transaction in Washington.

M&A Deal Summary
Date 2024-04-03
Target ProfoundBio
Sector Life Science
Buyer(s) Genmab
Deal Type Add-on Acquisition
Deal Value 1.8B USD
Advisor(s) BofA Securities
Morgan Stanley (Financial)
Cooley LLP
Jun He Law (Legal)

Target

ProfoundBio

Seattle, Washington, United States
website
ProfoundBio is a clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. ProfoundBio is based in Seattle, Washington.

Search 192,860 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genmab

Valby, Denmark

website

Category Company
Founded 1999
Sector Life Science
Revenue 16.5B DKK (2023)
DESCRIPTION

Genmab is an international biotechnology company using its antibody technology platform to offer bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function-enhanced antibodies, and antibody-drug conjugates. Genmab was formed in 1999 and is headquartered in Copenhagen, Denmark.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Washington) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal